Medicinski Centar Doverie AD
- Address
- lock Available on a paid plan
Crohn’s Disease
The research team at Medicinski Centar Doverie AD focuses on Crohn’s disease within the broader field of digestive system disorders, aiming to evaluate the safety and efficacy of emerging targeted therapies for patients with moderate to severe disease.
- Mechanistic profiling of novel agents
- Safety monitoring in inflammatory bowel disease
- Efficacy endpoints for disease remission
These studies seek to expand treatment options and improve long‑term outcomes for individuals coping with this chronic condition.
Ulcerative Colitis
At the same facility, investigators are comparing the safety and efficacy of lutikizumab versus adalimumab in adults with active ulcerative colitis, assessing adverse events and changes in disease activity.
- Comparative effectiveness of biologic agents
- Adverse event tracking and management
- Quantifying disease activity improvements
The goal is to identify more reliable therapeutic strategies that can reduce flare‑ups and enhance quality of life for patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG2active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medicinski Centar Doverie AD
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Lutikizumab Versus Adalimumab for Safety and Efficacy in Adults with Moderately to Severely Active Ulcerative Colitis | AbbVie Deutschland GmbH & Co. KG | Phase II | Not Yet Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Lutikizumab | 2 | Unknown | 2024-08-19 | 2024-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.